Multidisciplinary diagnostics of chronic lymphocytic leukemia: European Research Initiative on CLL - ERIC recommendations
AUTOR(ES)
Zalcberg, Ilana; D'Andrea, Mariana Gamma; Monteiro, Lucia; Pimenta, Glicínia; Xisto, Beth
FONTE
Hematol., Transfus. Cell Ther.
DATA DE PUBLICAÇÃO
2020-09
RESUMO
ABSTRACT Recent advances in chronic lymphocytic leukemia (CLL) includes description of disease genomic landscape, inclusion of prognostic relevant genetic tests in CLL workflow and evaluation of minimal residual disease (MRD)1 in parallel with the increase availability of novel therapy agents.In this review, the theoretical and practical aspects of response assessment have been discussed. These are based on updated recommendations of the European Research Initiative on Chronic Lymphocytic Leukemia (ERIC) for genetic tests (TP53 mutation and IGHV status) and flow cytometry analysis for CLL. Methodological approaches and interpretation of results were also discussed.2,3
Documentos Relacionados
- Diagnosis and treatment of chronic lymphocytic leukemia: recommendations from the Brazilian Group of Chronic Lymphocytic Leukemia
- Erratum to "Diagnosis and treatment of chronic lymphocytic leukemia: Recommendations from the Brazilian Group of Chronic Lymphocytic Leukemia" [Rev Bras Hematol Hemoter. 2016;38(4):346–357]
- Chronic lymphocytic leukemia: interplay between noncoding RNAs and protein-coding genes
- Editorial: Liver X receptor α (LXRα) as a therapeutic target in chronic lymphocytic leukemia (CLL)
- Lymphoblastoid cell lines from patients with chronic lymphocytic leukemia: identification of tumor origin by idiotypic analysis.
